Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.
In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more.
For pharma and biotech, in which data is the most valuable asset, industry analysts agree that digital transformation presents an opportunity to realize…
In our EuroBiotech roundup this week, Autolus advances CAR-T trial, Cell Medica names CSO and AB Science suffers a regulatory setback.
The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.
After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.
The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.
Researchers at Sanofi and the NIH have published preclinical evidence showing that a three-pronged approach may prevent HIV in healthy people.
VC Lightstone has $250 million in the bank for life science research.
Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.